Visual, Refractive, Functional, and Patient Satisfaction Outcomes After Implantation of a New Trifocal Diffractive Intraocular Lens

Javier Mendicute,1,2 Gorka Lauzirika,1,3 Igor Illarramendi,1 Itziar Martínez-Soroa1,2 1Miranza Begitek, Donostia - San Sebastián, 20012, Spain; 2Donostia University Hospital, Donostia - San Sebastián, 20014, Spain; 3R&D Department of Miranza Group, Donostia - San Sebastián, SpainCorrespondence: Gorka Lauzirika, Miranza Begitek, Teresa Calcutta Square, No. 7, Donostia - San Sebastián, 20012, Spain, Email [email protected]: To describe the visual, refractive, functional, and patient satisfaction outcomes of the Clareon® PanOptix® trifocal intraocular lens (IOL).Patients and Methods: This was a prospective longitudinal descriptive study. Patients who underwent cataract surgery with implantation of Clareon® PanOptix® (Alcon Laboratories, Inc.) were included. Monocular refractive outcomes and visual acuity at distance, intermediate, and near were evaluated 1- and 6-months post-op. Binocular contrast sensitivity (M&S® Technologies), binocular defocus curve, and patient satisfaction with the IOL Satisfaction (IOLSAT) and Questionnaire for Visual Disturbance (QUVID) questionaries were assessed at 6-month post-op.Results: Seventy-six Clareon® PanOptix® were implanted bilaterally in 38 patients. The mean age of the patients was 67.63± 5.18 years. At 1-month post-op, the monocular Corrected Distance Visual Acuity (CDVA), CIVA and CNVA were 0.00± 0.09, 0.02± 0.17, and 0.12± 0.12 LogMAR, respectively, and CDVA and CNVA were stable at 6-month post-op (p> 0.05). No statistical differences were found in post-op spherical equivalent at 1 and 6 months (− 0.08± 0.27 D and − 0.05± 0.24 D; p=0.351). A 100% of eyes were within ± 0.5 D at 1 month and 6-month post-op. Binocular defocus curve shows three peaks of maximum visual acuity (VA) at 0D (− 0.04± 0.08 LogMAR), at − 1.50D, and − 2.50 D (0.01± 0.10 LogMAR and 0.03± 0.07 LogMAR, respectively). Contrast sensitivity decreased at high spatial frequencies. In patient satisfaction, IOLSAT questionary reveals 78.94% patients “Never” or “Rarely” Needing Glasses and according QUVID questionnaire, 100% of patients report no hazy vision.Conclusion: The PanOptix® IOL platform with the new material Clareon® provides good visual outcomes for distance, intermediate, and near vision, with adequate contrast sensitivity and low visual disturbances.Keywords: cataract surgery, multifocal lens, vision restoration, phacoemulsification